Metalyse®
METALYSE® 25 MG IS NOW AVAILABLE FOR
THE FIBRINOLYTIC TREATMENT OF PATIENTS WITH ACUTE
ISCHAEMIC STROKE WITHOUT INTRACRANIAL HEMORRHAGE1
Because Every
Minute Matters
Stroke affects more than 12 million people each year. It is the second leading cause of death worldwide. Unfortunately, this number is only expected to rise because of an ageing global population.2
Acute ischaemic stroke (AIS) occurs when a vessel supplying blood to the brain is obstructed, depriving brain tissue of oxygen and nutrients. If blood flow is not restored fast enough, damage to brain cells in a particular area can lead to permanent disability and even death3-5. That’s why when it comes to stroke, every minute matters.
Time is brain
References
-
Metalyse® European Summary of Product Characteristics.
-
World Stroke Organization, https://www.world-stroke.org/world-stroke-day-campaign/about-stroke/impact-of-stroke.
-
American Heart Association, https://www.heart.org/-/media/files/health-topics/answers-by-heart/what-are-the-warning-signs-of-heart-attack.pdf
-
Donkor ES. Stroke Res Treat. 2018; 3238165.
-
Meretoja et al, Stroke. 2018
-
Saver JL. Stroke 2006; 37:263-266.